



WILEY

**RESEARCH ARTICLE**

Entangled decisions: Knowledge interdependencies and terminations of patented inventions in the pharmaceutical industry

Rajat Khanna¹ | Isin Guler² | Atul Nerkar²

¹Management Department, Tulane University, New Orleans, Louisiana

²Strategy and Entrepreneurship Department, Kenan-Flagler Business School, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Correspondence

Isin Guler, Kenan-Flagler Business School, University of North Carolina at Chapel Hill, McColl Building, Chapel Hill, NC 27599.
Email: guler@unc.edu

Research Summary: This study explores the role of knowledge interdependencies on the termination of patented inventions. Termination refers to the abandonment of inventive efforts that are no longer deemed promising. We argue that high interdependencies between an inventive effort and the other inventions in the same research program will increase the cognitive burden on managers and decrease the likelihood of termination. Further, in the presence of interdependencies, managers are likely to rely on heuristics for termination decisions. We focus on two such heuristics: interdependencies of an invention with those in other research programs and the level of external competition in the research program. We test our hypotheses with longitudinal data on patent terminations through non-payment of renewal fees in the pharmaceutical industry.

Managerial Summary: Effective management of innovation portfolios requires termination of opportunities that are no longer promising. Most current tools on termination assume that opportunities to be evaluated are independent from one another. This assumption may limit their usefulness in increasingly complex research domains, such as pharmaceutical R&D. In this study, we investigate how interdependencies among inventions influence firms' tendency to terminate those inventions. Our results on patent terminations show that a patent that is more interdependent with other patents in the same research program is less likely to be terminated. This suggests that managers may have difficulty in evaluating the inherent value of interdependent opportunities. This result is stronger when the patent is less interdependent with those in other research programs or in a more competitive area.

KEYWORDS

innovation, interdependencies, patents, R&D, termination

1 | INTRODUCTION

The portfolio problem is completely underestimated by almost every company in terms of complexity.
– Peter Mueller, Chief Scientific Officer, Vertex Pharmaceuticals.¹

Given the uncertainty involved in early stage R&D, many firms hold a portfolio of inventive efforts, which are constantly screened for further development through a multi-stage process. Along with the initial selection of projects from a pool of opportunities, the decisions to continue or terminate each inventive effort comprise a key competency in managing R&D portfolios. While recent work has begun to examine the determinants of effective termination practices (Guler, 2007; Joseph, Klingebiel, & Wilson, 2016), there has been little emphasis on how the structure of knowledge underlying R&D work may influence managerial decisions to continue or terminate a given inventive effort. In this paper, we ask how knowledge interdependencies among various inventions in an R&D portfolio affects termination decisions.

Studies of R&D project evaluation propose varied approaches to allocate scarce resources to the most appropriate research opportunities for further development (Brunner, Fleming, MacCormack, & Zinner, 2008 provides an excellent review). These models focus on the measurement of the expected economic value of each opportunity through simple net present value (NPV) calculations, or more complex real option valuation models (Amram & Kulatilaka, 1999; Dixit & Pindyck, 1994). This well-established and valuable literature has a key limitation in that none of the proposed approaches fully captures the challenges of portfolio management decisions in the real world (Cooper, Edgett, & Kleinschmidt, 2001). A key reason for this discrepancy is that the majority of studies examine continuation or termination decisions in isolation, without considering interdependencies. Few studies that have considered interdependencies typically focus on downstream interdependencies rather than those in terms of knowledge, which may differ in the challenges they pose in terms of valuation (e.g., Chan, Nickerson, & Owan, 2007; Vassolo, Anand, & Folta, 2004). In particular, as Brunner et al. (2008: 233) note, “almost all research to date on project and portfolio selection has ignored the interdependence that usually exists between projects...it is extremely difficult to understand the interactions between current projects and future learning and capability development.”

Interdependencies are especially important in contexts such as pharmaceuticals, where firms have typically been identified by the scale and scope of their research portfolios (Henderson & Cockburn, 1996). The discovery of drugs by companies in non-traditional therapeutic areas or even the emergence of new therapeutic areas is beyond one that could be explained by downstream synergies. For instance, Pfizer, a company focused on cardiovascular therapeutic area, launched the drug Viagra and created a new therapeutic area. Similarly, while GSK has traditionally been a company that focused

¹Pisano, Fleming & Strick, Vertex Pharmaceuticals (A), HBS Case 9-604-101.

on respiratory diseases, it now has products like Levitra, which competes with Viagra. Many drugs that were developed for a certain targeted disease have proved effective in treating other indications, such as Thalidomide, which has started out as a sedative, came to be used for treatment of nausea in pregnant women, was later revealed to have caused severe birth defects, and found new uses in the treatment of leprosy and multiple myeloma, a bone marrow cancer.² Similar examples point to the complex nature of pharmaceutical R&D and the role of knowledge interdependencies within and across research areas. Recent developments in drug development have contributed to the complexity of the R&D landscape. For instance, firms have increasingly been searching for drug candidates that target multiple pathways within therapeutic areas, such as multikinase inhibitors that target a single mechanism related with different types of cancer (Carroll, 2005). Moreover, the rise of biologics has contributed to drugs with higher complexity than before, such as AbbVie's Humira or Johnson & Johnson's Remicade, both of which are protected by over 100 patents (Koons, 2017). Increasingly, the modern pharmaceutical organization is moving towards a model-based drug discovery that values interdependence across different therapeutic areas through a deeper integrated understanding of the mechanisms at work in the human body (Morgan et al., 2012). The increase in interdependencies within and across research areas brings about the need to understand their implications for managerial decisions. Ignoring these interdependencies could lead to an incomplete or incorrect understanding of the research process.

In this study, we address this issue by focusing on how knowledge interdependencies surrounding an inventive effort influence managers' continuation or termination decisions.^{3,4} Our premise is that managers are boundedly rational yet proactive decision makers that aim to use termination decisions to shape adaptive search (Cyert & March, 1963). We assume that managers base a termination decision on their best estimate of the expected value of an invention. However, knowledge interdependencies within an invention portfolio increase decision complexity and make it more difficult for boundedly rational managers to evaluate the true value of a given invention, especially with respect to outcomes that are hard to measure, such as learning. Next, given the inability to make precise estimates of the inventions' future value, we argue that managers are likely to use heuristics in evaluating interdependent inventions. We focus on interdependencies across research programs and the level of external competition as two heuristics that may influence the termination of interdependent inventions. Using patent maintenance data between 1985 and 1999 in the pharmaceutical industry, we empirically show the relationship between knowledge interdependencies and patent terminations.

This study contributes to the literature on knowledge search and recombination by focusing on termination. Prior literature has examined in depth how firms search and recombine knowledge to generate novel outcomes (e.g., Fleming & Sorenson, 2004; Gavetti & Levinthal, 2000; Katila & Ahuja, 2002; Levinthal & March, 1981; Rosenkopf & Nerkar, 2001). In comparison, the process by which firms select among various outcomes of search efforts has been underplayed (Knudsen & Levinthal, 2007). Given that search and selection are essential components of choice (Simon, 1959), a focus on idea generation at the expense of selection might yield an imbalanced view of the process and capabilities leading to innovation (Arora, Gambardella, Magazzini, & Pammolli, 2009). This study complements the current literature on knowledge search and recombination by focusing on the process by which firms screen innovative ideas and shape their portfolios of knowledge.

²<https://blog.ted.com/9-old-drugs-that-learned-new-tricks-the-head-of-the-national-institutes-of-health-shares-medicines-that-turned-out-to-have-multiple-uses/>.

³We use inventive effort and invention interchangeably in this paper to refer to a research path that culminates in a patentable idea. We use innovation in a broader sense that includes commercialization of an invention.

⁴In our context, a firm makes a choice between continuing or terminating a given inventive effort, so continuation and termination decisions are mirror images of another. We focus on the termination decisions at a single decision point for each invention.

2 | INTERDEPENDENCE AND R&D AS SEARCH

Interdependence refers to interactions between components of a system such that the value of a particular component depends on the others (Levinthal, 1997), and changes to a component necessitate changes in other components as well (Ulrich, 1995). Interdependencies are often manifest as complementarity, in which “doing more of one thing increases the returns to doing more of another” (Milgrom & Roberts, 1995: 181), but may also generate negative externalities between components. The precise nature of the interdependencies may change in intensity or direction at different levels of their interaction or in the presence of other interdependent components. More importantly, the true nature of interdependencies is often unknown to the boundedly rational managers (Ethiraj & Levinthal, 2004b; Ghemawat & Levinthal, 2008).

Our examination of the relationship between knowledge interdependencies and termination of inventive efforts builds upon research on knowledge search and recombination and on complexity in innovation, as we detail below. We also briefly discuss the treatment of portfolio interdependencies in the corporate strategy literature.

Research on search and innovation in complex systems provides an important building block of this study by providing an understanding of inventive activity. The canonical depiction of search in innovation is as a process of experimentation through recombination of familiar and new components over time (Fleming & Sorenson, 2001; Fleming & Sorenson, 2004; Schumpeter, 1934). This process is complicated by at least two interrelated aspects. First, the number of potential recombinations of even a small number of components can become extremely large (Fleming & Sorenson, 2001). This makes it impossible for managers to comb through the whole universe of possible recombinations, given the cognitive and resource constraints. Second, interdependencies among knowledge components compound the difficulty of this task, since they further tax the cognitive capabilities of boundedly rational managers (Ethiraj & Levinthal, 2004a). Inventive efforts, therefore, comprise a good example of complex systems characterized by a large number of interdependent components (Simon, 1962). Decision making under complexity is often characterized as a search for solutions on a multi-dimensional problem terrain (Levinthal, 1997). In our setting, each useful invention corresponds to a solution, or a peak in the technological landscape (Fleming & Sorenson, 2001; Kauffman, Lobo, & Macready, 2000; Yayavaram & Ahuja, 2008). Value or usefulness of an invention is typically characterized by its subsequent use as a building block for future inventions (Fleming & Sorenson, 2001; Yayavaram & Ahuja, 2008).

The current study contributes to this perspective in several ways. First of all, it is one of the few studies that examine the implications of interdependencies among knowledge components for innovation rather than for product architectures or organizational structures (Fleming & Sorenson, 2001; Yayavaram & Ahuja, 2008; Yayavaram & Chen, 2015). Second, while earlier studies have typically focused on performance outcomes of knowledge interdependencies, to the best of our knowledge, our study is the first one to explore their impact on decisions to terminate individual inventions. Therefore, it provides a rare opportunity to examine an intermediate outcome that influences the performance of adaptive search.

Research in the economics tradition has also investigated the implications of interdependencies across inventions (Choi & Gerlach, 2014, 2017; Fershtman & Kamien, 1992; Gilbert & Katz, 2011). These studies typically examine the cases of complementary innovations that span inventive efforts across multiple firms, as in complex product systems (Ethiraj, 2007). They then explore the competitive implications of interdependent patent portfolios through formal models. Our study is distinct in

that we focus on interdependencies within a firm's own research portfolio, and their implications for terminations.

Our research echoes prior work in the corporate strategy literature on the impact of interdependencies on divestitures. For instance, Li and Chi (2013) have used a real options lens to highlight the importance of portfolio focus and diversity in venture capital investments, and Vassolo et al. (2004) have suggested that technological distance from the rest of the portfolio could influence dissolutions of a given alliance. Moreover, recent work suggests that interdependencies of routines among existing business units may increase the operational costs of divesting a business unit (Chang & Singh, 1999; Feldman, 2013; Karim, 2006; Natividad & Rawley, 2015). While the former set of studies focus on portfolios of external arrangements, such as venture capital and alliances, the latter focus on divestitures of divisions or business units. There are potentially important differences between operational interdependencies discussed in these studies and knowledge interdependencies within a research portfolio. For instance, shared operational routines are likely to be minimal and resource-dependence dynamics less pronounced in the case of knowledge interdependencies. At the same time, knowledge interdependencies may cause important path dependencies in how firms search and recombine knowledge, and influence how effectively firms learn from past experiences (Levinthal, 1997; Rivkin, 2000). A study of knowledge interdependencies and terminations of inventive effort could, therefore, yield different effects in substance and magnitude.

Armed with this background, we now turn to a discussion of how interdependencies in an R&D portfolio could play a role in decisions to continue or terminate a specific inventive effort.

2.1 | Interdependence and termination of inventive efforts

Termination decisions in portfolio management require detecting cues about the prospects of each inventive effort and acting on them. The content of the information may unveil deterioration in the value of an invention to a firm due to exogenous developments in science or technology, new competition, or changes in demand, or due to endogenous causes, such as a failure in project execution. Alternatively, a change in the firm's overall research direction may necessitate termination by decreasing the firm-specific value of the invention. Regardless of the underlying cause, termination of an inventive effort is an adaptive response that requires managers to process and act on new cues.

Interdependencies between inventions may make it difficult to act on such feedback, however. Interdependence increases complexity (Simon, 1962), which taxes managers' cognitive capabilities and their comprehension of cues, and makes it difficult for boundedly rational managers to grasp the underlying causal relationships (Ethiraj, Ramasubbu, & Krishnan, 2012; Fleming & Sorenson, 2001; March & Simon, 1958). In the presence of interdependencies, it is more challenging to anticipate the potentially cascading consequences of a change in one component of a complex system on all the other components (Ulrich, 1995), since the nature of interactions between the components is poorly understood (Ethiraj & Levinthal, 2004a). As a result, interdependencies may make it harder for firms to isolate a single inventive effort for termination. This could challenge the usefulness of multi-stage investment strategies, since adaptation through termination decisions cannot be implemented (Adner & Levinthal, 2004).

In the R&D context, managers may be concerned about terminating a particular inventive effort for several reasons. First, terminated efforts may embody knowledge that may be valuable for the remaining inventions in the firm's portfolio. To the extent that this knowledge is no longer accessible to the inventors in the firm, concurrent or subsequent inventive effort could be hurt. In the longer term, the absorptive capacity of the firm may be harmed due to the loss of a critical piece of interdependent knowledge (Cohen & Levinthal, 1990). Moreover, if inventors perceive terminations as a

signal of the firm's research direction (Ethiraj & Zhao, 2010), they may steer away from the underlying research, closing out possibilities of further recombinations. Second, owning interdependent innovations may enable the firm to appropriate higher returns from their R&D investments ex-post (Arora, Fosfuri, & Gambardella, 2001; Choi & Gerlach, 2017; Girotra, Terwiesch, & Ulrich, 2007; Teece, 1986). Removing inventions from the portfolio may then reduce the firm's ability to defend products from the competition.

When managers are unsure about the impact of a single termination on the expected value of the portfolio, they may refrain from termination decisions. To complicate the problem, the nature and extent of interdependencies may not be fully visible to managers until after the termination. Managers may sense that their firm could suffer performance losses if they disturb the internal fit between components by making a change in a single interdependent component (Kauffman, 1993; Levinthal, 1997; Rivkin, 2000), but not effectively estimate the nature and extent of those losses. These possibilities may deter managers from terminating inventive efforts even when the usefulness of the particular invention is subpar.

Hypothesis 1 (H1) *As the interdependence of an invention with the firm's other inventions in the same research program increases, the likelihood of the termination of the focal invention decreases.*

2.2 | Interdependencies across research programs and termination

When managers' cognitive limitations prevent them from making accurate estimations of the expected value of an inventive effort, they are likely to use heuristics in culling inventions (March & Simon, 1958). Heuristics are simple rules-of-thumb that help managers to organize knowledge in the face of high cognitive complexity and provide guidelines for action (Bingham & Eisenhardt, 2011; Newell & Simon, 1972). Scholars have characterized strategy and R&D processes as combinations of search heuristics (Nelson & Winter, 1977; Rivkin, 2000). Consistent with a growing literature, our perspective of heuristics is not as dysfunctional decision patterns, but as simplified rules that help firms satisfice on decision tasks (e.g., Bingham & Eisenhardt, 2011; Nelson & Winter, 1977; Newell & Simon, 1972).

Given the challenge of disentangling interdependent inventions, it is reasonable to expect managers to employ heuristics in complex termination decisions, as they do in search. Heuristics are especially likely to be helpful when the exact intrinsic value of an invention is hard to assess due to knowledge interdependencies. One such heuristic that may indirectly influence the termination decision has to do with interdependencies that cut across multiple research programs. Inventions that have interdependencies across research programs (along with interdependencies within a research program) may represent boundary-spanning knowledge (Rosenkopf & Nerkar, 2001). Managers may prefer to retain boundary-spanning inventions for several reasons. First, even when the expected value of an invention is hard to gauge due to knowledge interdependencies, inventions that span across research programs are more likely to offer high value due to fungibility and economies of scope (Anand & Singh, 1997). The knowledge contained in a boundary-spanning invention is likely to be useful in multiple research programs, and knowledge can be shared across multiple programs without loss of value (Arora et al., 2001; Henderson & Cockburn, 1996). Second, research that cuts across division and organizational boundaries is on average more novel, innovative, and likely to result in breakthroughs (Fleming & Waguespack, 2007; Rosenkopf & Nerkar, 2001; Uzzi, Mukherjee, Stringer, & Jones, 2013), even though it has higher variance in outcomes (Leahey, Beckman, &

Stanko, 2017; Singh & Fleming, 2010). Given the higher likelihood of a future breakthrough, and in the absence of invention-specific knowledge, managers may refrain from prematurely terminating such inventive paths. Third, many organizations may have in place rhetoric and norms that encourage boundary-spanning research (Leahey et al., 2017), and as such, managers may avoid or delay terminating such inventions in order to signal their support for them. Encouraging boundary-spanning research may especially be important since the difficulties of initiating and engaging in boundary-spanning research are well-documented (Bechky, 2003; Tortoriello & Krackhardt, 2010). Last, the consequences of terminating interdependent and boundary-spanning research may reverberate across the organization, leading to even larger unexpected negative outcomes, such as disrupting current inventive efforts of scientists, derailing learning outcomes and slowing the accumulation of absorptive capacity in multiple areas. Especially given that any single manager may lack the knowledge to evaluate an inventive effort that spans multiple areas, managers may delay or avoid postponing boundary-spanning research efforts as a heuristic.

While it is possible that the first order effect of boundary spanning on termination will be negative for these reasons, we maintain that the main criterion for any termination decision is the expected value of an invention to the firm. When the value is more easily ascertained, managers may not have to resort to heuristics in termination (e.g., Rivkin, 2000). In contrast, when knowledge interdependencies are high and the resultant complexity is too high for boundedly rational managers, we expect to clearly observe the influence of this heuristic on terminations.

Hypothesis 2 (H2) *All else equal, as the interdependencies of a patent with the other research programs in a firm's portfolio increases, the negative relationship between an invention's interdependencies within its research program and its likelihood of termination will be stronger.*

2.3 | External competition and termination

The extent of competition in a research program may also act as a heuristic in termination decisions when complexity is high due to knowledge interdependencies. Prior literature suggests that research that incorporates knowledge that is new to the world is more likely to result in more radical innovations (Ahuja & Lampert, 2001; Dewar & Dutton, 1986; Eggers & Kaul, 2018). Practitioners are also often encouraged firms to look for areas with little or no competition, rather than settling for a fraction of the profits available in a crowded competitive space (e.g., Kim & Mauborgne, 2005). As a result, managers may refrain from terminating inventive efforts in novel areas with little or no competition, given the higher potential for a breakthrough and a higher share of the potential profit. Conversely, given the reduced expected returns in areas where competition is higher, managers may be more willing to terminate interdependent experiments, all else equal. For instance, in pharmaceuticals, cardiovascular and anti-infective drugs represent crowded markets in which firms face reimbursement pressure and generic competition, which reduces the incentives to invest (Kaitin & DiMasi, 2011). In addition, new areas are where firms can stake their claims and signal their preemptive motives (Clarkson & Toh, 2010). Prior research suggests that, in the presence of complementary innovations, firms are particularly likely to crowd toward similar inventions for preemptive reasons (Choi & Gerlach, 2014, 2017). If managers sense that a firm can get there first, they may opt to maintain patents to preempt entry and limit future competition. Moreover, given that areas of exploration with little competitive activity and are poorly understood, managers may avoid early termination of

interdependent innovations because the amount of information required to evaluate such inventions is simply not available at early decision points.

In sum, the lack of competition in a research area may act as a heuristic to delay or avoid termination, given the potential upside of novelty, the level of uncertainty, and preemptive motives. As earlier, we expect firms to use this heuristic more intensely when there is more uncertainty about the value of any individual inventive effort; as a result, we expect competition to be more impactful on terminations decisions when knowledge interdependencies are high, all else equal.

Hypothesis 3 (H3) *All else equal, as the number of competitors in a specific a research program increases, the negative relationship between interdependencies and termination will be weaker.*

3 | CONTEXT: PHARMACEUTICAL DRUG DISCOVERY

We provide an empirical test of our hypotheses in pharmaceutical drug discovery. This area provides an appealing context to examine termination of inventive efforts for several reasons. First, the industry is highly research-intensive (Henderson & Cockburn, 1994). Prior research reports that patented inventions represent the majority of the innovative activities in this industry (e.g., Grabowski & Vernon, 1992; Levin, Klevorick, Nelson, & Winter, 1987). Patenting occurs at a higher rate (Arundel & Kabla, 1998; Chandy, Hopstaken, Narasimhan, & Prabhu, 2006; Cohen, Nelson, & Walsh, 2000; Paruchuri, Nerkar, & Hambrick, 2006) and starts earlier in research than in most other industries, long before tangible product outcomes (Lehman, 2003). This allows us to track inventive efforts in pharmaceutical research portfolios in a relatively comprehensive manner, and to observe the trajectories of innovation from early on in the process. Our study focuses on the research phase of pharmaceutical R&D, where firms search for chemical compounds that can then be the foundation of drug development (Henderson & Cockburn, 1994).

Second, given the low likelihood of achieving a commercially viable drug (DiMasi, Feldman, Seckler, & Wilson, 2010; Pisano, 2006), pharmaceutical firms typically file for and hold a large portfolio of patents at any given point in time. These portfolios comprise a nested structure of inventive effort at different levels, which makes them an excellent example of recombinant research (Fleming & Sorenson, 2001; Fleming & Sorenson, 2004; Schumpeter, 1934). It is possible to conceive of the human metabolism as a complex system with poorly understood interdependencies that are the target of pharmaceutical research. First-level components of that system are the research programs that represent therapeutic (disease) areas such as diabetes therapy or cardiology (Henderson & Cockburn, 1996). Research programs also reflect the internal organization of research within pharmaceutical firms, as they influence the boundaries of research and communication flows between research teams (Henderson & Clark, 1990; Henderson & Cockburn, 1996). Research under each program houses multiple patented inventions. We refer to each of these patented ideas as a specific invention, a building block for a larger project. In turn, each patented invention is often characterized as a recombination of multiple knowledge components (e.g., Fleming & Sorenson, 2001). In this way, pharmaceutical drug discovery exemplifies a hierarchical complex system that is composed of a succession of interrelated subsystems with their own subsystem (Sanchez & Mahoney, 1996; Simon, 1962).

Third, the industry provides an appealing context to study knowledge interdependencies between inventions in a portfolio. As the above discussion reveals, simultaneous research efforts within a firm

may have underlying knowledge components in common. Building on prior research that measures interdependencies through common knowledge components (e.g., Fleming & Sorenson, 2001; Sorenson, Rivkin, & Fleming, 2006; Yayavaram & Ahuja, 2008; Yayavaram & Chen, 2015), we are able to trace and measure the extent of interdependencies between inventive efforts. Moreover, since pharmaceutical firms typically undertake inventive efforts in multiple therapeutic areas, we are able to consider interdependencies within and across therapeutic areas. This gives us a unique opportunity to understand how interdependencies influence the management of research portfolios at a given level of individual patent performance.

Finally, the drug discovery and development process has distinct stages at which firms choose to pursue or terminate inventive efforts. Apart from the FDA-enforced clinical trials, pharmaceutical firms must pay renewal fees to maintain their intellectual property rights on each patent at 4, 8, and 12 years after the grant date (Harhoff, Narin, Scherer, & Vopel, 1999; Lanjouw & Schankerman, 2004; Moore, 2005; Serrano, 2010). Given the large upfront outlays in research, low costs of renewal, and alternative means of deploying patents such as licensing and sales, termination of a patent represents a deliberate decision to terminate a research path^{5,6} (Appendix A provides a detailed review of the literature on patent terminations). In fact, as opposed to clinical trials, which often occur much later in the discovery and development process, and are typically terminated due to exogenous failures in trial outcomes (Arora et al., 2009), patent terminations provide an earlier and more comprehensive window into deliberate adaptive responses in the pharmaceutical industry (DiMasi, 2001; Khanna, Guler, & Nerkar, 2016). Compounds in the preclinical stage comprise about half of all pharmaceutical research (Ding, Dong, Eliashberg, & Gopalakrishnan, 2014). Moreover, early terminations are important to contain the high development costs in the pharmaceutical industry, where failures in late-stage trials are extremely costly: “if a drug is going to fail, it should fail quickly” (Shillingford & Vose, 2001: 942).

4 | METHODS

4.1 | Data

Our analysis combines the data on termination of inventions, characteristics of research programs in a firm's research portfolio, and competitive landscape in the pharmaceutical industry. We first compiled all patents categorized in United States Patent and Trademark Office (USPTO) patent classes 424 and 514 (drug, bio-affecting and body treating compositions) between 1985 and 1999. This led to a total of 100,065 patents that belonged to more than 200 firms. Since we are interested in firms that engage in formal R&D, we removed firms that did not patent for at least five consecutive years in the study period (Cuervo-Cazurra & Un, 2010). Also, many of these patents only had a minor application in the pharmaceutical industry and were focused on knowledge areas outside pharmaceuticals. Therefore, we removed patents with a primary class other than 424 or 514 to be certain that our sample focused on inventions within the pharmaceutical industry. These two steps reduced the sample size to 8,256 patents owned by 102 firms. After accounting for missing values of variables used in this study, empirical models are based on 7,124 patents for 85 firms.

⁵In this paper, we use termination to refer to the firm giving up the intellectual property rights on a patented invention through non-payment of periodic renewal fees. This is distinct from expirations that occur at the end of the 20-year patent term, and abandonments at the application stage.

⁶It is important to note that an invention that is not terminated is not automatically considered successful, but still has to go through a long and arduous process of development to lead to a viable product.

TABLE 1 Research programs: IMS Health's uniform system of classification (USC)

2 Analgesics	24 Genitourinary	38 Anti-Fungal Agents	67 Sedatives
9 Antiarthritics	28 Respiratory Therapy	39 Diabetes Therapy	69 Smoking Deterrents
11 Hemostatic Modifiers	29 Cardiac Agents	41 Diuretics	74 Tuberculosis Therapy
14 Antihistamines, Systemic	30 Antineoplastic Agents	48 Blood Growth Factors	78 Miscellaneous Preps
15 Anti-Infectives, Systemic	31 Vascular Agents	52 Hormones	82 Antiviral
17 Antinauseants	32 Antihyperlipidemic Agents	59 Musculoskeletal	85 Sexual Function Disorders
18 Anti-Obesity	33 Contraceptives	60 Nutrients & Supplements	86 Immunologic Agents
20 Neurological Disorders	34 Cough/Cold Preparations	61 Ophthalmic Preparations	
23 Gastrointestinal	37 Dermatologicals	64 Psychotherapeutics	

4.2 | Variables

We measure termination of inventive efforts using the termination of pharmaceutical patents through a failure to pay renewal fees 4 years after the grant date. Based on the discussion in the prior section and Appendix A, and following prior work (Khanna et al., 2016; Serrano, 2010), it is our contention that non-renewal of patents represent deliberate terminations, and firms commit resources to identifying and terminating less valuable patents as a part of their portfolio management strategy.⁷ We collect patent termination data from the USPTO, which provides detailed information on patents that are terminated due to nonpayment of maintenance fees. We only focus on terminations at the 4-year mark in order to capture the early phases of research, and limit heterogeneity in the nature and motives for terminations that may arise at later decision points. The dependent variable, patent termination, is binary and is coded as one if a patent got terminated 4 years after grant date and zero otherwise. Of the 7,124 patents in our sample, approximately 19% were terminated 4 years after the grant date.

The independent variable is the interdependence of the focal patent with the other patents in the same research program within the firm's research portfolio. We define research programs based on the classification created by IMS Health. IMS Health's Uniform System of Classification (USC) classifies pharmaceutical drugs into 34 therapeutic categories, such as analgesics, anti-obesity, and respiratory therapy, which we use to identify research programs. Table 1 presents the codes and descriptions of these 34 categories. The USPTO, however, does not categorize patents into same categories and instead assigns subclasses to each patent (>2,000 subclasses in the pharmaceutical industry). With the help of a trained expert in pharmacology, we map the USPTO-assigned subclasses onto USC's 34 categories (a detailed concordance matrix that connects the USPTO classes to the IMS Health categories is available as an Table S1). We then identify the key research program for each patent based on the highest number of subclasses of a patent that map onto a USC category. For example, if three of the five subclasses of a patent map onto USC category 9, the patent is assigned to that category. In a few cases where there is no dominant category, we use the first subclass that appeared in the patent to identify the USC category. Patents in a firm's portfolio that belong to the same therapeutic area comprise the firm's research program in that area.

After assigning each patent to a research program, we calculate our independent variable, i.e., *interdependence of the patent within its research program*. The premise behind the interdependence measure for a patent is that subclasses assigned to a patent represent the knowledge

⁷It is possible that a firm fails to renew a patent out of neglect rather than deliberate motives. These can be reversed within a set grace period, and such patents will be renewed after a short lapse if important to the firm. We remove those from our consideration set in the empirical analysis to capture deliberate terminations.

components comprising the patent, and the extent of shared knowledge components between two patents represents their interdependence (Fleming, 2001; Fleming & Sorenson, 2004; Ganco, 2013). Following tradition, we create a network of patents within a research program in each firm using subclasses as nodes and common patents as edges. Next, we take the average of the degree centralities of the subclasses underlying a patent to estimate the interdependence of the patent with all the other patents in the same research program. The measure essentially captures how frequently subclasses that are part of a patent are combined with subclasses of other patents in the same research program. Higher interdependence of a patent indicates that its subclasses are combined more frequently with the other subclasses in the research program. The steps to calculate interdependence can be summarized mathematically:

$$I_{a,i,j} = \frac{\sum_{x \in a} \text{centrality of } x \text{ in network of patents in firm } i \text{ and research program } j}{\text{count of subclasses of patent } a} \quad (1)$$

where $I_{a,i,j}$ is interdependence of patent a in firm i in research program j with other patents in research program j . The numerator in Equation (1) is the sum of centralities of subclasses (x) that are assigned to patent a in the network of patents in research program j in firm i . The denominator is the count of subclasses of patent a .

The first moderating variable used in this study is *interdependence across research programs*, i.e., interdependence of a given patent in a research program with patents that are in the other research programs in the firm's portfolio. The measure is constructed using the same methodology, except patents that are considered to construct the network are different. Mathematically, it can be described as:

$$IO_{a,i,j} = \frac{\sum_{x \in a} \text{centrality of } x \text{ in network of patents in firm } i \text{ and outside research program } j}{\text{count of subclasses of patent } a} \quad (2)$$

where $IO_{a,i,j}$ is interdependence of patent a in firm i in research program j with patents outside research program j . The measure captures the extent to which knowledge components (captured by subclasses) of patent a are combined with subclasses of patents in other research programs. We then calculate the average interdependence of all patents within a research program to arrive at our measure.

The second moderating variable is the *extent of external competition*, which we measure as the number of other firms that have at least one patent in the same therapeutic area as the focal patent. The measure is weighted by number of each firm's patents in the same therapeutic area to account for the size of each competitor in the area. Formally:

$$C_{a,i,j,k} = \frac{\sum_{j \in a} \text{number of firms with } k \text{ patents in research program } j \times k}{\sum \text{number of firms}} \quad (3)$$

$C_{a,i,j,k}$ in Equation (3) measures the extent of competition for patent a in firm i and research program j . The Equation (3) shows the weighted sum of the number of firms in our sample that have at least one patent in research program j of patent a , with weights as the number of each firm's patents ($= k$) in research program j . We interact these two measures with a patent's interdependence within its research program to test our hypotheses.

We also include several control variables that can affect our outcome variable. First, we control for the number of forward citations received by each patent at the year of renewal or termination, since prior work has found that patents with more citations are not only more valuable to firms (Jaffe, Trajtenberg, & Henderson, 1993; Pavitt, 1988; Trajtenberg, 1990), but are also less likely to be

terminated (Serrano, 2010). Previous research has shown that number of claims on a patent indicates the number of novel contributions the patent makes and can be a significant predictor of the future value of the patent (Lanjouw & Schankerman, 2004; Tong & Frame, 1994). Since valuable patents are less likely to be terminated, we control for the number of claims for each patent. At the research program level, we control for the main effects of interdependence with other research programs and the extent of external competition.

We control for time-invariant firm properties that may influence termination with firm fixed effects. Additionally, we control for several time-varying firm-level properties. Prior literature has shown that firms that diversify into multiple technologies benefit from technological spillovers, buffer themselves against the risk of investments in a single technology, and get exposed to new opportunities and innovation (Jaffe, 1986; Nelson, 1959). Therefore, strategically undertaking ideas in technologically diverse areas can change firms' decisions to terminate inventions that are under consideration (Li & Chi, 2013). We control for technological diversity as the Herfindahl Index for subclasses in which a firm patented in a given year. Next, firms conducting R&D across multiple countries can access and leverage resources that are not available in the home country (Kobrin, 1991). Thus, we control for the number of countries in which firms in our sample filed patents. A firm's decision to terminate a project could be endogenous to the way it conducts R&D. It is possible that some firms generate more patents and terminate more of them. Empirically, we account for this by controlling for productivity, the number of patents granted to each firm. A firm's decision to terminate a patent in a research program may be influenced by its existing R&D capabilities in that program (Cohen & Levinthal, 1990). Therefore, we controlled for the stock of the firm's patents within each program. Last, we control for the number of alliances that firms made in a given year, since firms' decisions to enter into an alliance, especially in a high technology industry, are often driven by their strategy to enhance their R&D capabilities (Sampson, 2007) and can potentially influence their decision to terminate patents. All control variables, except those at the patent level, are measured using a 3-year moving average window ($t-3$ to $t-1$) to smooth out sharp changes and control for lasting effects. We also included year dummies in the model to control for time-specific trends in the data.

4.3 | Empirical approach

In our sample, each observation represents a patent, and the dependent variable, termination, takes the value of one if the patent is terminated 4 years after grant date and zero if it is renewed. A logit model is a natural choice when the dependent variable is binary. The model estimates the probability that a patent will be terminated as a function of a series of independent, moderating, and control variables with the form:

$$P_{a,i,j,t} = \frac{e^{\beta_1 X_{a,i,j,t-1} + \beta_2 C_{a,i,j,t-1} + \beta_3 C_{i,t-3-t-1}}}{1 + e^{\beta_1 X_{a,i,j,t-1} + \beta_2 C_{a,i,j,t-3-t-1} + \beta_3 C_{i,t-3-t-1}}} \quad (4)$$

$P_{a,i,j,t}$ in Equation (4) is the probability that patent a in research program j in firm i will be terminated. $X_{a,i,j,t-1}$ is the vector of independent and moderating variables including interdependence of a patent within a research program, interdependence across research programs, and extent of competition for patent a in research program j in firm i in year $t-1$. Independent and moderating variables are measured in $t-1$ to avoid simultaneity in the regression equation. $C_{a,i,j,t-3-t-1}$ consists of control variables that are at the patent level and include number of citations and claims for patent a in research program j in firm i . $C_{i,t-3-t-1}$ is a matrix of control variables at the firm level and consists of technological diversity, number of countries, productivity, and number of alliances for firm i ,

measured as moving average of values of these variables between $t-3$ and $t-1$. The model includes fixed firm and year effects. We conducted a Hausman test to identify the preferred model between fixed effects and random effects, and p -value ($= .017$) from the Hausman test suggested the use of a fixed effects model.

5 | RESULTS

Table 2 presents the descriptive statistics and correlation matrix for variables used in this paper. Since some of the interaction terms are highly correlated with the main effects, we checked the variance inflation factors (VIF) and found that the VIF for the overall model is 1.62, within the acceptable range. In addition, we determined that our results met only one of the three criteria outlined by Kalnins (2018) that could raise concerns about Type I errors due to multicollinearity. We therefore conclude that multicollinearity is not a significant concern.

Table 3 summarizes the results from our fixed-effects logistic models. Model 1 in Table 3 contains only control variables. The coefficient on productivity is positive and has a p -value of .007, suggesting that a patent is more likely to be terminated when the firm has acquired more patents in the previous period. Also, the number of citations to a patent decreases the likelihood that a patent will get terminated, although the effect is weak.

In Hypothesis 1, we predicted that a patent's likelihood of termination would decline with an increase in its interdependence with the other patents in the same research program. Model 2 in Table 3 tests this relationship. The coefficient of interdependence within the research program is -3.16 at a p -value of .020, indicating a considerable decrease in likelihood of termination of a patent with an increase in interdependence. A one standard-deviation increase in a patent's interdependence within the research program ($=0.039$) decreases the odds of patent termination by 4%.⁸ We therefore find support for Hypothesis 1.

Hypothesis 2 predicted that interdependence across research programs would exacerbate the relationship between interdependence of a patent within the research program and the patent's probability of termination. The coefficient on the interaction term is negative with a p -value of .18 in Table 3, Model 3. The p -value of .18 confers weak evidence of a significant role of the moderating variable. As logit is a non-linear model, we avoid making any interpretations on the direction of effect of moderating variables based on the sign of its coefficient in regression model (Hoetker, 2007; Norton, Wang, & Ai, 2004; Zelner, 2009). We use the "margins" command in Stata to plot the relationship between interdependence within a research program and predicted probability of a patent's termination at different levels of interdependence (minimum = 0, mean = 0.015, and mean + one standard deviation = ~ 0.03) across research programs (Williams, 2012). As almost 98% of the values of interdependence within a research program fall between 0 and 0.1 in our sample, we used this range to plot the relationship. As shown in Figure 1,⁹ the likelihood of a patent's termination decreases at a faster rate at higher values of interdependence across research programs. When the interdependence across research programs is zero, there is a decrease in the probability of a patent's termination from

⁸A coefficient of -3.16 amounts to odds ratio of 0.0424 ($=e^{-3.16}$), which suggests odds of termination are 96% ($=0.0424-1$) lower for a unit increase in interdependency. Thus, for an increase in patent's interdependence within the research program by one standard-deviation ($=0.039$), we see a decrease of 4% in odds of patent termination ($=e^{-3.16}-1$) $*0.039$.

⁹Since we plotted the interactions between values of 0 and 0.1 for interdependence within a research program, the plot seems linear in nature as opposed to typical S-shaped curve in case of logit model. We plotted the same relationship for all values of interdependence within a research program i.e., between 0 and 1 and extrapolated values of interdependence within a research program i.e., between -1 and 1. The plot (Appendix B) confirms that the relationship is S-shaped; consistent with the form of logistic function. The same applies to Figure 2.

TABLE 2 Descriptive statistics and partial correlations

Variables	Mean	SD	Min	Max	1	2	3	4	5	6	7	8	9	10	11	12	13
1. Patent termination	0.192	0.394	0	1	1												
2. Interdependence within research program	0.016	0.039	0	0.45	-0.02	1											
3. Interdependence across research program	0.014	0.011	0	1	-0.01	-0.32	1										
4. Interdependence within research program X interdependence across research programs	0.00024	0.0002	0	0.012	-0.01	0.81	0.23	1									
5. Interdependence within research program X extent of competition	0.038	0.29	0	11	0.01	0.14	-0.08	0.40	1								
6. Extent of competition	25.80	42.27	0	347	-0.01	0.05	0.05	-0.12	0.41	1							
7. Patents in research program	13.54	13.36	4	80	-0.02	0.02	0.01	0.01	0.09	0.22	1						
8. Number of citations	5.604	7.331	0	156	-0.03	0.04	0.08	0.06	0.01	-0.00	0.05	1					
9. Number of claims	11.66	3.718	1	96	0.02	0.03	0.11	-0.03	-0.09	-0.03	0.12	0.07	1				
10. Technological diversity	0.106	0.311	0.01	3,469	-0.01	0.10	0.00	0.03	-0.00	0.01	-0.01	0.01	-0.08	1			
11. Number of countries	1.347	1.049	1	7	0.00	0.02	0.04	0.03	-0.02	0.10	0.08	0.01	-0.02	-0.04	1		
12. Productivity	458.1	493.3	1	2,311	0.05	-0.11	-0.08	-0.14	-0.07	0.07	0.02	-0.01	0.42	-0.15	0.26	1	
13. Number of alliances	1.598	1.634	0	17	0.02	0.21	-0.15	0.30	0.29	0.09	0.02	-0.02	0.62	-0.04	-0.01	0.11	1

TABLE 3 Fixed-effects logistic model estimates for patent termination (DV = likelihood of patent termination)

Variable	1	2	3	4	5					
Interdependence within research program		−3.16 (1.34)	.020	−0.55 (2.32)	.812	−4.40 (1.51)	.004	−1.16 (2.38)	.628	
Interdependence within research program × interdependence across research programs				−201.03 (152.50)	.180			−265.36 (158.70)	.094	
Interdependence within research program × extent of competition						.39 (0.18)	.028	.47 (0.20)	.012	
Interdependence across research programs	−3.23 (3.24)	.319	−3.42 (3.24)	.291	−1.53 (3.51)	.661	−3.49 (3.24)	.281	−3.42 (3.24)	.759
Extent of competition	−0.00 (0.00)	.479	−0.01 (0.01)	.463	−0.01 (0.01)	.476	−0.01 (0.01)	.165	−0.01 (0.01)	.138
Patents in research program	0.00 (0.00)	.903	0.00 (0.00)	.943	0.00 (0.00)	.938	0.00 (0.00)	.976	0.00 (0.00)	.969
Number of citations	−0.01 (0.01)	.170	−0.01 (0.01)	.170	−0.01 (0.01)	.170	−0.01 (0.01)	.177	−0.01 (0.01)	.178
Number of claims	0.05 (0.01)	.005	0.05 (0.01)	.004	0.04 (0.01)	.004	0.05 (0.01)	.002	0.05 (0.01)	.002
Technological diversity	0.16 (0.14)	.283	0.16 (0.15)	.267	0.16 (0.15)	.272	0.16 (0.15)	.264	0.16 (0.15)	.271
Number of countries	−0.01 (0.03)	.667	−0.01 (0.04)	.694	−0.01 (0.03)	.714	−0.01 (0.03)	.741	−0.01 (0.04)	.774
Productivity	0.00 (0.00)	.007	0.00 (0.00)	.011	0.00 (0.00)	.011	0.00 (0.00)	.009	0.00 (0.00)	.010
Number of alliances	−0.03 (0.03)	.356	−0.00 (0.03)	.996	−0.00 (0.03)	.968	−0.00 (0.03)	.910	−0.00 (0.03)	.951
Year dummies	YES	YES	YES	YES	YES	YES	YES	YES	YES	
Wald χ^2	92.60	98.60	100.41	100.41	102.49	102.49	105.44	105.44	105.44	
χ_p^2	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
# Observations	7,124	7,124	7,124	7,124	7,124	7,124	7,124	7,124	7,124	
# Groups	85	85	85	85	85	85	85	85	85	

Standard errors in parentheses, p-values in bold.

12% to 10% as the interdependence within the research program increases from 0 to 0.1. When interdependence across research programs is at one standard deviation above the mean, the probability of a patent's termination decreases from approximately 12% to 5% for the same increase in the interdependence within the research program. While the p -value of .094 in the full model (Model 5) suggests some noise in the influence of interdependency across research programs on the relationship between interdependency within research program and innovation performance, the effect size is considerable; the probability of a termination of a patent decreases 5% more for an increase in interdependency within research program from 0 to 0.1, when interdependency across research programs is one standard deviation above the mean compared to when interdependency across research programs is at the minimum. Thus, the set of findings outlined above provides some evidence and does not lead us to entirely rule out the effect of moderating role of interdependency across research programs. The




FIGURE 1 Relationship between predicted probability of termination of a patent and its interdependence within the research program at different levels of interdependence across research programs

future research in this field can inform us more about the strength of the relationships tested here. In addition, we find that the main effect of the interdependence of the patent across research programs is not significant, suggesting that it acts as a heuristic only in the presence of interdependencies within the research program.

Results from Model 4 in Table 3 provide support for Hypothesis 3, which predicts that the extent of external competition in the therapeutic area of the focal patent will attenuate the relationship between a patent's interdependence within the research program and its likelihood of termination. The coefficient on the extent of competition is positive (0.39) at a p -value of .028. Figure 2 presents the plot of the relationship between predicted the likelihood of termination of a patent and its interdependence within the research program at different levels of competition (minimum = 0, mean




FIGURE 2 Relationship between predicted probability of termination of a patent and its interdependence within the research program at different levels of extent of competition

= 25.8, and mean + standard deviation = 68). When there is no competition, the probability of termination of a patent decreases from 25% to 14% as the interdependence within the research program increases from 0 to 0.1. When the competition is at one standard deviation above the mean, for an equal increase in interdependence within a research program, the probability of termination of a patent decreases from 23% to 17%. These results indicate that at higher levels of competition, the negative relationship between interdependence and termination is weaker, supporting Hypothesis 3. An interesting result is that when interdependence within a research program is below a certain value (<0.03), firms are more likely to give up a patent when competition is at a minimum. This could reflect termination of ad hoc research outcomes in areas with no interdependencies and no competition, as a result of a low likelihood of leading to a promising drug. At low levels of interdependencies, when it is relatively easier to evaluate value of projects independently, firms may have a higher tendency to terminate experiments in such areas. In addition, we find that the main effect of competition is not significant, consistent with our proposed mechanism of the importance of heuristics under complexity.

5.1 | Robustness analyses

An important alternative explanation for our results is that interdependent inventions represent learning outcomes and not complexity, as we have suggested. If firms gain absorptive capacity by searching in interdependent areas, their termination patterns may reflect superior learning. Similarly, competitors may represent a higher collective knowledge accumulation in an area, so that firms can learn vicariously from competitors (Krieger, 2017). In order to examine this alternative explanation, we generated an interaction term between a firm's past patent stock in a given research program and the level of interdependencies. The firm's patent stock in a research program is an indicator of knowledge accumulation in that program, especially given the widespread practice of patenting in pharmaceuticals. If indeed absorptive capacity increases through interdependent research activity, and influences terminations due to a superior understanding of underlying linkages, this interaction term should have a significant impact on termination. As we present in Table 4, Models 1 and 2, we do not observe a significant interaction between the firm's patent stock in a research program and interdependencies. In addition, we do not observe a significant main effect of the firm's patent stock in a research program on terminations, either. These findings suggest that the knowledge accumulation through directed effort may not be underlying our results. Moreover, our results are robust to the introduction of this interaction effect. Given that learning from other firms' experience is typically harder than learning from a firm's own experience, especially in the presence of complexity (Rivkin, 2000; Winter & Szulanski, 2001), we conclude that the results are unlikely to reflect vicarious learning. As an additional robustness test to distinguish between competition as a heuristic and as a tool for vicarious learning, we removed the weighting of the competition variable by the number of each firm's patents in order to avoid capturing knowledge accumulation instead of competition. Models 3 and 4 in Table 4 show that the results are generally robust, providing further support for our arguments. These results could reflect the possibility that learning is challenging and absorptive capacity is hard to build under interdependencies, but require further research that is beyond the scope of this study.

Second, since it is possible that termination decisions in the same research program or firm portfolio are not independent, we investigated whether the observed relationships between interdependence and termination hold if we move the unit of analysis to research programs and firms. First, we modified the dependent variable to reflect the number of patents terminated in a research program by a firm in each year. The independent and moderating variables are calculated as averages of patents'

TABLE 4 Robustness tests – fixed effects logistic models (DV = likelihood of patent termination)

Variable	1	2	3	4				
Interdependence within research program	−3.500 (1.76)	.046	−0.31 (2.52)	.900	−3.16 (1.34)	.020	−0.86 (2.36)	.714
Interdependence within research program × interdependence across research programs			−255.98 (154.66)	.098			−277.79 (160.1)	.082
Interdependence within research program × extent of competition			0.66 (0.26)	.016			4.96 (2.16)	.014
Interdependence within research program × patents in research program	0.02 (0.03)	.756	−0.08 (0.08)	.328				
Interdependence across research programs	−3.42 (3.24)	.291	−1.16 (3.50)	.740	−3.42 (3.24)	.291	−0.98 (3.51)	.779
Extent of competition	−0.00 (0.00)	.455	−0.01 (0.01)	.094	−0.15 (0.13)	.257	−0.25 (0.14)	.075
Patents in research program	−0.00 (0.00)	.973	0.00 (0.00)	.748	0.00 (0.00)	.882	0.00 (0.00)	.967
Number of citations	−0.01 (0.01)	.172	−0.01 (0.01)	.178	−0.01 (0.01)	.163	−0.01 (0.01)	.171
Number of claims	0.05 (0.01)	.004	0.05 (0.01)	.003	0.04 (0.02)	.004	0.05 (0.01)	.002
Technological diversity	0.16 (0.14)	.266	0.16 (0.15)	.276	0.16 (0.15)	.278	0.15 (0.15)	.287
Number of countries	−0.01 (0.03)	.695	−0.01 (0.03)	.788	−0.01 (0.04)	.708	−0.01 (0.03)	.802
Productivity	0.00 (0.00)	.011	0.00 (0.00)	.009	0.00 (0.00)	.008	0.00 (0.00)	.007
Number of alliances	−0.03 (0.03)	.985	−0.01 (0.03)	.959	−0.00 (0.03)	.988	−0.00 (0.03)	.952
Year dummies	YES		YES		YES		YES	
Wald χ^2	98.69		106.45		99.37		106.01	
χ_p^2	0.00		0.00		0.00		0.00	
# Observations	7,124		7,124		7,124		7,124	
# Groups	85		85		85		85	

Standard errors in parentheses, p-values in bold.

interdependencies within each research program, across research programs, and the level of competition in a given research program each year. The control variables, number of citations and claims, are also the averages of values for all patents in the research program. Other research program and firm-level control variables are the same as in the main analysis. We used negative binomial models with fixed effects since the dependent variable is a non-negative integer. Table 5, Models 1 and 2 present the results. We then repeated a similar analysis at the firm level rather than the program level. The results are presented in Models 3 and 4 in Table 5. The findings are consistent with those obtained in

TABLE 5 Fixed-effects negative binomial model estimates for intensity of patent termination

Variable	1	2	3	4				
Interdependence within research program	-2.57 (0.26)	.000	-2.60 (0.26)	.000	-6.07 (1.40)	.000	-7.01 (1.51)	.000
Interdependence within research program × interdependence across research programs			-6.46 (4.10)	.116			-23.14 (14.34)	.106
Interdependence within research program × extent of competition			0.02 (0.00)	.000			0.03 (0.02)	.036
Interdependence across research programs	-5.72 (0.25)	.000	-6.00 (0.52)	.005	-4.15 (1.48)	.000	-5.01 (1.51)	.001
Extent of competition	0.01 (0.00)	.000	0.01 (0.00)	.000	0.04 (0.01)	.000	0.04 (0.01)	.002
Patents in research program	0.00 0.00	.516	0.00 0.00	.898	0.00 0.00	.898	0.00 0.00	.921
Number of citations	-0.00 (0.01)	.037	-0.00 (0.01)	.991	-0.00 (0.01)	.986	-0.00 (0.01)	.879
Number of claims	0.00 (0.00)	.186	0.00 (0.00)	1.00	0.00 (0.00)	.998	0.00 (0.00)	.951
Technological diversity	0.03 (0.02)	.184	0.03 (0.02)	.350	-0.09 (0.10)	.354	-0.10 (0.10)	.305
Number of countries	-0.15 (0.09)	.116	-0.16 (0.10)	.341	-0.34 (0.36)	.340	-0.42 (0.36)	.240
Productivity	0.00 (0.00)	.000	0.00 (0.00)	.032	0.00 (0.00)	.031	0.00 (0.00)	.026
Number of alliances	0.24 (0.03)	.000	0.24 (0.02)	.004	0.17 (0.06)	.004	0.22 (0.06)	.000
Constant	0.64 (0.11)	.000	0.65 (0.11)	.349	0.37 (0.40)	.356	0.34 (0.40)	.388
Firm fixed effects	YES		YES		YES		YES	
Year dummies	YES		YES		YES		YES	
Wald χ^2	2,365		2,388		233		242	
χ_p^2	0.00		0.00		0.00		0.00	
# Observations	14,821		14,821		821		821	
# Groups	1,462		1,462		85		85	

Models 1, 2: Dependent variable is the number of patents abandoned in a research program. Models 3, 4: Dependent variable is the number of patents abandoned by the firm. Standard errors in parentheses, p-values in bold.

hypothesis tests. Interestingly, we observe in this model that the main effect of competition is positive and significant, along with the interaction effect between competition and interdependencies. This could suggest that firms may be more likely to give up clumps of interdependent knowledge under conditions of competition and complexity.

In unreported results, we also tested whether the relationship between interdependence and termination is curvilinear. We did not find evidence for a curvilinear relationship within the range of observed variables in our data set.

6 | DISCUSSION AND CONCLUSIONS

This study generated several interesting insights. Controlling for the value of an invention, we find that interdependencies between the invention and others in the same research program influence whether the invention is likely to be terminated or not. This result points to the challenge of evaluating the value of an individual invention for the overall research endeavor in the presence of interdependencies. We also find some evidence that interdependencies across research programs exacerbate this effect, and competition in the research program attenuates it. We attribute these findings to heuristics managers use in evaluating interdependent inventions.

These findings offer several key contributions. First, our work contributes to the literature on search and selection by demonstrating how firms use terminations as part of their innovation strategy. Variations in firms' search strategies in terms of the intensity and content of their innovation efforts, influence how effectively firms can use terminations as an adaptation tool. This suggests that search and termination capabilities may be interrelated, and firms may follow different strategies in how they couple these competencies. The observed connections between the two stages of innovation invite more research.

In addition, the finding that managers prefer to keep projects in areas that span research domains and those with lower competition under conditions of interdependencies reveals an interesting asymmetry between initial search and later termination: While prior research suggests that firms may err toward local and path dependent search (e.g., Ahuja & Lampert, 2001), our results highlight that, once a search effort that is boundary spanning or new to the world is initiated, managers prefer to continue rather than terminate it, especially under high complexity.

This study also contributes to the literature on project termination and continuation. Prior literature often documents the challenges of termination decisions in different contexts (e.g., Horn, Lovallo & Viguerie, 2006; Dranikoff, Koller & Schneider, 2002, Guler, 2007). A prominent set of explanations for this observation is escalation of commitment, or a bias to continue investment even in the face of bad news (Staw, 1976, 1981) due to the limitations of decision makers or organizations. However, other scholars point out that decisions that appear to be biased at the outset may in fact reflect a rational tendency to wait due to uncertainty (Elfenbein & Knott, 2015). Our study provides an alternative perspective to inform this debate, and shows that a tendency to continue innovation projects may be contingent on the knowledge structure underlying those projects. When interdependencies increase the complexity of termination decisions, managers may opt to retain projects for longer. This result suggests that it is important to consider the characteristics or structure of the projects themselves for a thorough understanding of termination decisions.

Next, our study also extends the work on how projects are terminated using a real options framework. In particular, it joins prior work that suggests boundary conditions for the use of real options logic (Adner, 2007; Adner & Levinthal, 2004) by highlighting how knowledge interdependencies influence project decisions. While in typical real options models, managers may be able to identify and value complementarities or substitution effects (Vassolo et al., 2004), knowledge interdependencies are difficult to value, due to the uncertainty in knowledge creation, as well as a poor understanding of the knowledge structures and ties across research areas. As a result, our results suggest that the complexity of R&D may decrease the usefulness of real options models in evaluating projects.

Last, our work has implications for project termination in the context of larger firms with multiple research programs as opposed to smaller specialist firms with single research programs.

In general, firms holding portfolios of projects in multiple research areas may be more effective at termination decisions (Lowe & Ziedonis, 2006), reflecting the advantages that larger firms may have at information gathering and evaluation. At the same time, our results suggest that the advantage of large firms may be dissipated if the research work is interdependent and hard to evaluate. Along with downstream interdependencies in complementary assets (Chan et al., 2007), upstream interdependencies in knowledge creation may influence the project selection process.

This study can be extended in several ways. First, we rely on patent data to capture the inventive effort within pharmaceutical firms. Even though firms in the pharmaceutical industry patent most of their ideas (Cohen et al., 2000; Levin et al., 1987), we could still be missing ideas that were eliminated before the patenting stage. Future studies could aim to capture a more comprehensive population of all ideas and their progression in the development cycle. In addition, identifying projects with multiple patents could be beneficial. Even though we believe this omission provides a more conservative test of our hypotheses (interdependent patents, if they belong to the same project, would be terminated together, causing a positive correlation between interdependence and likelihood of termination), a new study with this control would be helpful. Third, even though we have presented theory and results consistent with the mechanism of cognitive limitations and decision heuristics, we have no direct way of observing actual decisions. Our approach to heuristics is consistent with a stream that views them as helpful and simplified decision rules (Bingham & Eisenhardt, 2011; Nelson & Winter, 1977; Newell & Simon, 1972), and our results do not preclude the possibility that the resulting decisions may be the optimal ones in a given situation. Future work that can provide in-depth observations of termination decisions in the field could enrich these initial findings. Fourth, although there are some advantages to limiting the scope of current study to the pharmaceutical industry, the findings may not generalize across other industries. Last, the current study does not discuss the performance implications of changes in decision making as a result of interdependencies. Future work that can link the variation in terminations as a result of interdependencies and firms' innovation performance can further our understanding of innovation process.

To conclude, our research underlines the importance of termination as an adaptive tool. Given the high rates of termination observed in the pharmaceutical industry, we find that firms use terminations strategically to shape portfolios of inventive effort. We submit that managers should approach termination decisions proactively, as they are both prevalent and important. Researchers and managers should not underestimate the importance of interdependencies in portfolio evaluations. Our study suggests that interdependencies in research portfolios may influence not only the effectiveness of search, but also firms' selection strategies.

ACKNOWLEDGEMENTS

We are grateful to the Editor and two anonymous reviewers for their guidance. We thank Anne Marie Knott and the participants in the Academy of Management Meetings presentation for their insightful comments and suggestions.

REFERENCES

- Adner, R. (2007). Real options and resource allocation processes: Real options theory. *Advances in Strategic Management*, 24, 363–372.
- Adner, R., & Levinthal, D. A. (2004). What is not a real option: Considering boundaries for the application of real options to business strategy. *Academy of Management Review*, 29(1), 74–85.

- Ahuja, G., & Lampert, C. M. (2001). Entrepreneurship in the large corporation: A longitudinal study of how established firms create breakthrough inventions. *Strategic Management Journal*, 22(6–7), 521–543.
- Amram, M., & Kulatilaka, N. (1999). *Real options: Managing strategic investment in an uncertain world*. Boston, MA: Harvard Business School Press.
- Anand, J., & Singh, H. (1997). Asset redeployment, acquisitions and corporate strategy in declining industries. *Strategic Management Journal*, 18(Special Issue Supplement), 99–118.
- Arora, A., Fosfuri, A., & Gambardella, A. (2001). Markets for technology and their implications for corporate strategy. *Industrial & Corporate Change*, 10(2), 419–451.
- Arora, A., Gambardella, A., Magazzini, L., & Pammolli, F. (2009). A breath of fresh air? Firm type, scale, scope, and selection effects in drug development. *Management Science*, 55(10), 1638–1653.
- Arundel, A., & Kabla, I. (1998). What percentage of innovations are patented? Empirical estimates for European firms. *Research Policy*, 27(2), 127–141.
- Bechky, B. A. (2003). Sharing meaning across occupational communities: The transformation of understanding on a production floor. *Organization Science*, 14(3), 312–330.
- Bingham, C. B., & Eisenhardt, K. M. (2011). Rational heuristics: The "simple rules" that strategists learn from process experience. *Strategic Management Journal*, 32(13), 1437–1464.
- Brunner, D., Fleming, L., MacCormack, A., & Zinner, D. (2008). R&D project selection and portfolio management: A review of the past, a description of the present, and a sketch of the future. In S. Shane (Ed.), *Handbook of technology and innovation management*. West Sussex: Wiley.
- Carroll, J. (2005). One drug, many uses. *Biotechnology Healthcare*, 2(5), 56–61.
- Chan, T., Nickerson, J. A., & Owan, H. (2007). Strategic management of R&D pipelines with cospecialized investments and technology markets. *Management Science*, 53(4), 667–682.
- Chandy, R., Hopstaken, B., Narasimhan, O., & Prabhu, J. (2006). From invention to innovation: Conversion ability in product development. *Journal of Marketing Research*, 43(3), 494–508.
- Chang, S. J., & Singh, H. (1999). The impact of modes of entry and resource fit on modes of exit by multibusiness firms. *Strategic Management Journal*, 20(11), 1019–1035.
- Choi, J. P., & Gerlach, H. (2014). Selection biases in complementary R&D projects. *Journal of Economics & Management Strategy*, 23(4), 899–924.
- Choi, J. P., & Gerlach, H. (2017). A theory of patent portfolios. *American Economic Journal: Microeconomics*, 9(1), 315–351.
- Clarkson, G., & Toh, P. K. (2010). Keep out' signs: The role of deterrence in the competition for resources. *Strategic Management Journal*, 31(11), 1202–1225.
- Cohen, W. M., & Levinthal, D. A. (1990). Absorptive capacity: A new perspective on learning and innovation. *Administrative Science Quarterly*, 35(1), 128–152.
- Cohen WM, Nelson RR, Walsh J. 2000. *Protecting their intellectual assets: Appropriability conditions and why U.S. manufacturing firms patent (or not)* (Working Paper, National Bureau of Economic Research No. w7552).
- Cooper, R., Edgett, S., & Kleinschmidt, E. (2001). Portfolio management for new product development: Results of an industry practices study. *R&D Management*, 31(4), 361–380.
- Cuervo-Cazurra, A., & Un, C. (2010). Why some firms never invest in formal R&D. *Strategic Management Journal*, 31(7), 759–779.
- Cyert, R., & March, J. G. (1963). *A behavioral theory of the firm*. Englewood Cliffs, NJ: Prentice Hall.
- Dewar, R. D., & Dutton, J. E. (1986). The adoption of radical and incremental innovations: An empirical analysis. *Management Science*, 32(11), 1422–1433.
- DiMasi, J. A. (2001). Risks in new drug development: Approval success rates for investigational drugs. *Clinical Pharmacology & Therapeutics*, 69, 297–307.
- DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010). Trends in risks associated with new drug development: Success rates for investigational drugs. *Clinical Pharmacology and Therapeutics*, 87(3), 272–277.
- Ding, M., Dong, S., Eliashberg, J., & Gopalakrishnan, A. (2014). Portfolio management in new drug development. In M. Ding, J. Eliashberg, & S. Stremersch (Eds.), *Innovation and marketing in the pharmaceutical industry*. New York, NY: Springer.
- Dixit, A. K., & Pindyck, R. S. (1994). *Investment under uncertainty*. Princeton, NJ: Princeton University Press.
- Dranikoff, L., Koller, T., & Schneider, A. (2002). Divestiture: Strategy's missing link. *Harvard Business Review*, 80(5), 74–83.
- Eggers, J., & Kaul, A. (2018). Motivation and ability? A behavioral perspective on the pursuit of radical invention in multi-technology incumbents. *Academy of Management Journal*, 61(1):67–93.
- Elfenbein, D. W., & Knott, A. M. (2015). Time to exit: Rational, behavioral and organizational delays. *Strategic Management Journal*, 36(7), 957–975.
- Ethiraj, S. K., & Zhao, M. (2010). Macro practices of R&D management and micro behaviors of scientists. *Academy of Management Annual Meeting Proceedings*, 2010(1), 1–6. <https://doi.org/10.5465/ambpp.2010.54496924>
- Ethiraj, S. K. (2007). Allocation of inventive effort in complex product systems. *Strategic Management Journal*, 28(6), 563–584.
- Ethiraj, S. K., & Levinthal, D. (2004a). Bounded rationality and the search for organizational architecture: An evolutionary perspective on the design of organizations and their evolvability. *Administrative Science Quarterly*, 49(3), 404–437.
- Ethiraj, S. K., & Levinthal, D. (2004b). Modularity and innovation in complex systems. *Management Science*, 50(2), 159–173.

- Ethiraj, S. K., Ramasubbu, N., & Krishnan, M. S. (2012). Does complexity deter customer-focus? *Strategic Management Journal*, 33(2), 137–161.
- Feldman, E. R. (2013). Legacy divestitures: Motives and implications. *Organization Science*, 25(3), 815–832.
- Fershtman, C., & Kamien, M. I. (1992). Cross licensing of complementary technologies. *International Journal of Industrial Organization*, 10(3), 329–348.
- Fleming, L. (2001). Recombinant uncertainty in technological search. *Management Science*, 47(1), 117–132.
- Fleming, L., & Sorenson, O. (2001). Technology as a complex adaptive system: Evidence from patent data. *Research Policy*, 30, 1019–1039.
- Fleming, L., & Sorenson, O. (2004). Science as a map in technological search. *Strategic Management Journal*, 25(8–9), 909–928.
- Fleming, L., & Waguespack, D. M. (2007). Brokerage, boundary spanning, and leadership in open innovation communities. *Organization Science*, 18(2), 165–180.
- Ganco, M. (2013). Cutting the Gordian knot: The effect of knowledge complexity on employee mobility and entrepreneurship. *Strategic Management Journal*, 34(6), 666–686.
- Gavetti, G., & Levinthal, D. (2000). Looking forward and looking backward: Cognitive and experiential search. *Administrative Science Quarterly*, 45(1), 113–137.
- Ghemawat, P., & Levinthal, D. (2008). Choice interactions and business strategy. *Management Science*, 54(9), 1638–1651.
- Gilbert, R. J., & Katz, M. L. (2011). Efficient division of profits from complementary innovations. *International Journal of Industrial Organization*, 29(4), 443–454.
- Girotra, K., Terwiesch, C., & Ulrich, K. T. (2007). Valuing R&D projects in a portfolio: Evidence from the pharmaceutical industry. *Management Science*, 53(9), 1452–1466.
- Grabowski, H. G., & Vernon, J. M. (1992). Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. *The Journal of Law & Economics*, 35(2), 331–350.
- Guler, I. (2007). An empirical examination of real options in U.S. venture capital industry. In J. Reuer & T. Tong (Eds.), *Advances in Strategic Management* (Vol. 24). New York: Elsevier/JAI.
- Harhoff, D., Narin, F., Scherer, F. M., & Vopel, K. (1999). Citation frequency and the value of patented inventions. *Review of Economics & Statistics*, 81(3), 511–515.
- Henderson, R., & Cockburn, I. (1994). Measuring competence? Exploring firm effects in pharmaceutical research. *Strategic Management Journal*, 15, 63–84.
- Henderson, R., & Cockburn, I. (1996). Scale, scope, and spillovers: The determinants of research productivity in drug discovery. *RAND Journal of Economics*, 27(1), 32–59.
- Henderson, R. M., & Clark, K. B. (1990). Architectural innovation: The reconfiguration of existing product technologies and the failure of established firms. *Administrative Science Quarterly*, 35(1), 9–30.
- Hoetker, G. (2007). The use of logit and probit models in strategic management research: Critical issues. *Strategic Management Journal*, 28(4), 331–343.
- Horn, J. T., Lovallo, D. P., & Viguier, S. P. (2006). Learning to let go: Making better exit decisions. *McKinsey Quarterly*, 2, 65–75.
- Jaffe, A. B. (1986). *Technological opportunity and spillovers of R&D: Evidence from firms' patents, profits and market value*. (Working Paper No. 1815). Cambridge, MA: National Bureau of Economic Research. <https://doi.org/10.3386/w1815>
- Jaffe, A. B., Trajtenberg, M., & Henderson, R. (1993). Geographic localization of knowledge spillovers as evidenced by patent citations. *The Quarterly Journal of Economics*, 108(3), 577–598.
- Joseph, J., Klingebiel, R., & Wilson, A. J. (2016). Organizational structure and performance feedback: Centralization, aspirations, and termination decisions. *Organization Science*, 27(5), 1065–1083.
- Kaitin, K. I., & DiMasi, J. A. (2011). Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000–2009. *Clinical Pharmacology & Therapeutics*, 89(2), 183–188.
- Kalnins, A. (2018). Multicollinearity: How common factors cause Type 1 errors in multivariate regression. *Strategic Management Journal*, 39(8), 2362–2385. <https://doi.org/10.1002/smj.2783>
- Karim, S. (2006). Modularity in organizational structure: The reconfiguration of internally developed and acquired business units. *Strategic Management Journal*, 27(9), 799–823.
- Katila, R., & Ahuja, G. (2002). Something old, something new: A longitudinal study of search behavior and new product introduction. *Academy of Management Journal*, 45(6), 1183–1194.
- Kauffman, S., Lobo, J., & Macready, W. G. (2000). Optimal search on a technology landscape. *Journal of Economic Behavior & Organization*, 43(2), 141–166.
- Kauffman, S. A. (1993). *The origins of order: Self-organization and selection in evolution*. New York: Oxford University Press.
- Khanna, R., Guler, I., & Nerkar, A. (2016). Fail often, fail big, and fail fast? Learning from small failures and R&D performance in the pharmaceutical industry. *Academy of Management Journal*, 59(2), 436–459.
- Kim, W. C., & Mauborgne, R. (2005). Blue ocean strategy. *California Management Review*, 47(3), 105–121.
- Knudsen, T., & Levinthal, D. A. (2007). Two faces of search: Alternative generation and alternative evaluation. *Organization Science*, 18(1), 39–54.
- Kobrin, S. (1991). An empirical analysis of the determinants of global integration. *Strategic Management Journal*, 12(1), 17–31.
- Koons C. (2017). This Shield of Patents Protects the World's Best-Selling Drug. *Bloomberg Businessweek* September 7, 2017. Retrieved from <https://www.bloomberg.com/news/articles/2017-09-07/this-shield-of-patents-protects-the-world-s-best-selling-drug>.

- Krieger, J. L. (2017). *Trials and terminations: Learning from competitors' R&D failures* (Working Paper No. 18-043). Harvard Business School.
- Lanjouw, J. O. (1998). Patent protection in the shadow of infringement: Simulation estimations of patent value. *The Review of Economic Studies*, 65(4), 671–710.
- Lanjouw, J. O., & Schankerman, M. (2004). Patent quality and research productivity: Measuring innovation with multiple indicators. *The Economic Journal*, 114(495), 441–465.
- Leahey, E., Beckman, C. M., & Stanko, T. L. (2017). Prominent but less productive: The impact of Interdisciplinarity on Scientists' research. *Administrative Science Quarterly*, 62(1), 105–139.
- Lehman, B. (2003). *The pharmaceutical industry and the patent system*. Washington, DC: International Intellectual Property Institute.
- Levin, R. C., Klevorick, A. K., Nelson, R. R., & Winter, S. G. (1987). Appropriating the returns from industrial research and development. *Brookings Papers on Economic Activity*, 3, 783–833.
- Levinthal, D., & March, J. G. (1981). A model of adaptive organizational search. *Journal of Economic Behavior & Organization*, 2(4), 307–333.
- Levinthal, D. A. (1997). Adaptation on rugged landscapes. *Management Science*, 43(7), 934–950.
- Levitas, E., & Chi, T. (2010). A look at the value creation effects of patenting and capital investment through a real options lens: The moderating role of uncertainty. *Strategic Entrepreneurship Journal*, 4(3), 212–233.
- Li, Y., & Chi, T. (2013). Venture capitalists' decision to withdraw: The role of portfolio configuration from a real options lens. *Strategic Management Journal*, 34(11), 1351–1366.
- Liu, K. (2014). Human capital, social collaboration, and patent renewal within US pharmaceutical firms. *Journal of Management*, 40(2), 616–636.
- Liu, K., Arthurs, J., Cullen, J., & Alexander, R. (2008). Internal sequential innovations: How does interrelatedness affect patent renewal? *Research Policy*, 37(5), 946–953.
- Lowe, R. A., & Veloso, F. M. (2015). Patently wrong? Firm strategy and the decision to disband technological assets. *European Management Review*, 12(2), 83–98.
- Lowe, R. A., & Ziedonis, A. A. (2006). Overoptimism and the performance of entrepreneurial firms. *Management Science*, 52(2), 173–186.
- March, J. G., & Simon, H. A. (1958). *Organizations*. New York: Wiley.
- Milgrom, P., & Roberts, J. (1995). Complementarities and fit: Strategy, structure, and organizational change in manufacturing. *Journal of Accounting & Economics*, 19(2–3), 179–208.
- Moore, K. A. (2005). Worthless patents. *Berkeley Technology Law Journal*, 20, 1521.
- Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. (2012). Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. *Drug Discovery Today*, 17(9–10), 419–424.
- Natividad, G., & Rawley, E. (2015). Interdependence and performance: A natural experiment in firm scope. *Strategy Science*, 1(1), 12–31.
- Nelson, R. R. (1959). The economics of invention: A survey of the literature. *Journal of Business*, 32(2), 101–127.
- Nelson, R. R., & Winter, S. G. (1977). In search of useful theory of innovation. *Research Policy*, 6(1), 36–76.
- Newell, A., & Simon, H. A. (1972). *Human problem solving*. Englewood Cliffs, NJ: Prentice-Hall.
- Norton, E. C., Wang, H., & Ai, C. (2004). Computing interaction effects and standard errors in logit and probit models. *Stata Journal*, 4, 154–167.
- Pakes, A. (1986). Patents as options: Some estimates of the value of holding European patent stocks. *Econometrica*, 54(4), 755–784.
- Paruchuri, S., Nerkar, A., & Hambrick, D. C. (2006). Acquisition integration and productivity losses in the technical core: Disruption of inventors in acquired companies. *Organization Science*, 17(5), 545–562.
- Pavitt, K. (1988). Uses and abuses of patent statistics. In A. van Raan (Ed.), *Handbook of Quantitative Studies of Science and Technology*. Amsterdam: Elsevier.
- Pisano, G. (2006). *The science business: The promise, the reality, and the future of biotech*. Boston: Harvard Business School Press.
- Reitzig, M. (2004). Strategic management of intellectual property. *MIT Sloan Management Review*, 45(3), 35.
- Rivkin, J. (2000). Imitation of complex strategies. *Management Science*, 46(6), 824–844.
- Rosenkopf, L., & Nerkar, A. (2001). Beyond local search: Boundary-spanning, exploration, and impact in the optical disk industry. *Strategic Management Journal*, 22(4), 287–306.
- Sampson, R. C. (2007). R&D alliances and firm performance: The impact of technological diversity and alliance organization on innovation. *Academy of Management Journal*, 50(2), 364–386.
- Sanchez, R., & Mahoney, J. T. (1996). Modularity, flexibility, and knowledge management in product and organization design. *Strategic Management Journal*, 17(Winter), 63–76.
- Schankerman, M. (1998). How valuable is patent protection? Estimates by technology field. *The Rand Journal of Economics*, 29, 77–107.
- Schankerman, M., & Pakes, A. (1986). Estimates of the value of patent rights in European countries during the post-1950 period. *The Economic Journal*, 96(384), 1052–1076.
- Schumpeter, J. (1934). *The theory of economic development*. Oxford: Oxford University Press.
- Scotchmer, S. (1999). On the optimality of the patent renewal system. *The Rand Journal of Economics*, 30, 181–196.

- Serrano, C. J. (2010). The dynamics of the transfer and renewal of patents. *The Rand Journal of Economics*, 41(4), 686–708.
- Shillingford, C. A., & Vose, C. W. (2001). Effective decision-making: Progressing compounds through clinical development. *Drug Discovery Today*, 6(18), 941–946.
- Simon, H. A. (1959). Theories of decision-making in economics and behavioral science. *American Economic Review*, 49(3), 253–283.
- Simon, H. A. (1962). The architecture of complexity. *Proceedings of the American Philosophical Society*, 106, 467–482.
- Singh, J., & Fleming, L. (2010). Lone inventors as sources of breakthroughs: Myth or reality? *Management Science*, 56(1), 41–56.
- Somaya, D. (2012). Patent strategy and management an integrative review and research agenda. *Journal of Management*, 38(4), 1084–1114.
- Sorenson, O., Rivkin, J. W., & Fleming, L. (2006). Complexity, networks and knowledge flow. *Research Policy*, 35(7), 994–1017.
- Staw, B. M. (1976). Knee-deep in the big muddy: A study of escalating commitment to a chosen course of action. *Organizational Behavior and Human Performance*, 16(1), 27–44.
- Staw, B. M. (1981). Escalation of commitment to a course of action. *Academy of Management Review*, 6(4), 577–587.
- Teece, D. J. (1986). Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy. *Research Policy*, 15(6), 285–305.
- Tong, X., & Frame, J. D. (1994). Measuring national technological performance with patent claims data. *Research Policy*, 23(2), 133–141.
- Tortoriello, M., & Krackhardt, D. (2010). Activating cross-boundary knowledge: The role of simmelian ties in the generation of innovations. *Academy of Management Journal*, 53(1), 167–181.
- Trajtenberg, M. (1990). A penny for your quotes: Patent citations and the value of innovations. *RAND Journal of Economics*, 21(1), 172–187.
- Ulrich, K. (1995). The role of product architecture in the manufacturing firm. *Research Policy*, 24(3), 419–440.
- Uzzi, B., Mukherjee, S., Stringer, M., & Jones, B. (2013). Atypical combinations and scientific impact. *Science*, 342(6157), 468–472.
- Vassolo, R. S., Anand, J., & Folta, T. B. (2004). Non-additivity in portfolios of exploration activities: A real options-based analysis of equity alliances in biotechnology. *Strategic Management Journal*, 25(11), 1045–1061.
- Williams, R. (2012). Using the margins command to estimate and interpret adjusted predictions and marginal effects. *Stata Journal*, 12(2), 308–331.
- Winter, S. G., & Szulanski, G. (2001). Replication as strategy. *Organization Science*, 12(6), 730–743.
- Yayavaram, S., & Ahuja, G. (2008). Decomposability in knowledge structures and its impact on the usefulness of inventions and knowledge-base malleability. *Administrative Science Quarterly*, 53(2), 333–362.
- Yayavaram, S., & Chen, W. R. (2015). Changes in firm knowledge couplings and firm innovation performance: The moderating role of technological complexity. *Strategic Management Journal*, 36(3), 377–396.
- Zelner, B. A. (2009). Using simulation to interpret results from logit, probit, and other nonlinear models. *Strategic Management Journal*, 30(12), 1335–1348.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Khanna R, Guler I, Nerkar A. Entangled decisions: Knowledge interdependencies and terminations of patented inventions in the pharmaceutical industry. *Strat Mgmt J*. 2018;39:2439–2465. <https://doi.org/10.1002/smj.2923>

APPENDIX A: Patent Renewal Process Summary

A patent granted by the USPTO has a 20-year term from filing. The assignee must, however, pay a maintenance fee to renew the patent at four, eight, and 12 years. A failure to do so results in termination of the patent protection. Maintenance fees are modest: In 2018, the 4-, 8-, and 12-year renewal fees are \$1,600, \$3,600, and \$7,400, respectively. When a firm does not renew a patent, it is plausible to infer that the expected value of the patent for the firm is below these rates (e.g., Lanjouw, 1998; Pakes, 1986; Schankerman & Pakes, 1986). Considering that a firm can extract value from a patent in a multitude of ways, including commercialization, legal action, transfer, or licensing (e.g., Levitas & Chi, 2010;

Reitzig, 2004; Somaya, 2012), termination of a patent is a good indicator of the patent's (lack of) value to the firm. Indeed, patent renewals are associated with indicators of expected value, such as the number of forward citations (Harhoff et al., 1999; Lanjouw & Schankerman, 2004; Moore, 2005; Serrano, 2010).

Moore (2005) suggests that the rates of termination underline the role of renewal fees as an innovation sorting mechanism. Average patent renewal rates are below 50% (Lanjouw, 1998; Pakes, 1986; Schankerman, 1998), but vary by technology and country (Schankerman, 1998; Scotchmer, 1999). For instance, the rates of termination are higher in biotechnology and pharmaceuticals than in computer hardware and software (Moore, 2005). Biotechnology and pharmaceutical companies patent even the smallest ideas earlier in the development process, relying on sorting at later stages, whereas computer companies patent tangible products and technologies (Lehman, 2003; Moore, 2005).

Examination of patent terminations in strategy is relatively recent. Scholars find that terminations are related to the type of research and characteristics of the inventors (Liu, 2014; Liu, Arthurs, Cullen, & Alexander, 2008; Lowe & Veloso, 2015). Examining how firms learn from terminations, Khanna et al. (2016) found a link between terminations and subsequent R&D performance.

APPENDIX B: Plots of interactions for all values of interdependence




FIGURE B1 Plot of relationship between predicted probability of termination of a patent and its interdependence within the research program: values of interdependence within research programs between 0 and 1




FIGURE B2 Plot of Relationship Between Predicted Probability of Termination of a Patent and Its Interdependence Within the Research Program: Values of Interdependence within Research Programs Between -1 and 1